Loading...
Remdesivir is FDA approved for treating hospitalized patients with COVID-19 pneumonia. Now, in the manufacturer-sponsored trial known as PINETREE, investigators asked whether remdesivir improved outcomes in non-hospitalized, high-risk patients with mild-to-moderate COVID-19. A planned enrollment of >1200 participants was closed early for administrative reasons, including the advent of anti-SARS-CoV-2 monoclonal antibodies as standard of care for this population. The trial ultimately involved 562 unvaccinated patients with ≥1 risk factor for severe COVID-19 and ≤7 days of symptoms (median duration, 5 days). Participants were randomized to receive intravenous remdesivir (200 mg on day 1, 100 mg on days 2 and 3) or placebo.
Incidence of COVID-1…